Are Semaglutides Safe? What the Clinical Evidence Actually Shows

What large-scale trials tell us about semaglutide's safety record

The STEP programme is the most substantial source of safety data on semaglutide 2.4mg for weight management. The STEP 1 trial, published in the New England Journal of Medicine, ran for 68 weeks and consistently showed that the most common adverse events were nausea, diarrhoea and vomiting, unpleasant, but not dangerous for most people, and generally transient. Discontinuation rates due to side effects were higher than placebo but still a minority of participants.

Regulatory scrutiny adds another layer of reassurance. The MHRA reviewed this data before granting a UK licence, and Wegovy's Black Triangle designation keeps it under active post-market surveillance. That isn't a warning sign, it is standard practice for newer medicines, and it means any emerging safety signals get picked up and acted on quickly.

A common misconception is that because these medicines suppress appetite so effectively, they must be doing something drastic or unsafe to the body. If you are wondering whether it is safe to take semaglutide, the mechanism (activating GLP-1 receptors involved in appetite signalling and blood-sugar regulation, and slowing gastric emptying) is a modulation of existing physiology, not a bypass of it. That distinction matters when you are weighing up the evidence.

You can explore the full picture of semaglutide's benefits and side effects in more detail if you want to go deeper on the trial numbers before your consultation.

The side effects most people actually experience

The NHS medicines page for semaglutide sets out the known side-effect profile clearly. Gastrointestinal effects dominate: nausea is the most frequently reported, followed by constipation, diarrhoea, vomiting, indigestion and burping. Fatigue, headache and dizziness also appear in the common category.

Timing matters here. These effects tend to cluster around the first few weeks of treatment and after each dose increase. Many people find that eating smaller portions, avoiding very fatty meals and staying well hydrated keeps them manageable. The escalating dose schedule (starting low and increasing gradually) exists partly to reduce this burden.

Less common effects include hair thinning; if that is a concern you have, our page on whether semaglutides cause hair loss covers what the evidence actually says. Similarly, some people notice fatigue that goes beyond the usual adjustment period, that question has its own dedicated page at do semaglutides make you tired.

Injection-site reactions (redness, itching or a small lump) are also possible and usually minor. Rotating the injection site between your abdomen, thigh and upper arm with each weekly dose reduces the likelihood.

Worth checking before you start: semaglutide is not recommended during pregnancy, while breastfeeding, or if you are actively trying to conceive. It is not licensed for anyone under 18. A history of pancreatitis, medullary thyroid carcinoma or MEN2 requires careful prescriber discussion before any GLP-1 treatment is considered.

When to get medical help, and what signs to take seriously

Most side effects from semaglutide are self-limiting and manageable. A handful of rarer effects require prompt medical attention, and knowing them in advance is straightforward and useful.

Acute pancreatitis is an infrequent but serious risk associated with GLP-1 medicines. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting this: if you develop severe, persistent stomach pain that radiates to your back (with or without vomiting) stop treatment and seek urgent medical care. Do not wait to see if it passes.

Other signs that warrant prompt attention include: symptoms of gallbladder problems (sudden pain in the upper right abdomen, particularly after eating); signs of serious dehydration from prolonged vomiting or diarrhoea (dizziness, very dark urine, inability to keep fluids down); any allergic reaction such as swelling of the face or throat, or difficulty breathing; and significant changes in mood or thoughts of self-harm, which should be reported to a prescriber or GP straight away.

If you are taking oral contraceptives alongside tirzepatide (a different GLP-1 medicine), specific additional precautions apply during dose changes, but for semaglutide, current NHS guidance does not identify equivalent evidence of reduced pill effectiveness. Your prescriber can advise based on your full medication list.

You can report any suspected side effect (including from a product you are unsure about) at the MHRA's Yellow Card scheme. It takes minutes and contributes directly to ongoing safety monitoring for everyone using these medicines.

Long-term safety and what we still do not know for certain

The honest answer about whether semaglutide is safe is: the picture is increasingly reassuring but still developing. The longest published trials run to around 68–72 weeks, which is a meaningful period but not a decade. Cardiovascular data for semaglutide is notably positive (the SELECT trial showed a reduction in major cardiovascular events in eligible adults) and this has since been incorporated into a separate UK licence indication. That is a safety signal moving in the right direction.

What remains under active study is the effect of very long-term use and what happens to weight, metabolism and other markers over many years. The ongoing surveillance that the MHRA's Black Triangle status facilitates means new findings will be acted on as the evidence base grows.

For a fuller look at the existing evidence on safety over time, the dedicated page on semaglutide's long-term safety goes through the available data carefully. And if you are ready to discuss your own health history and what semaglutide might mean for you specifically, start your free consultation, a real prescriber reviews it the same day, not a form-processing algorithm.